If everything goes as planned, the deal will give the $45-billion Pfizer the tax benefits of an Iri…

Unfortunately, my warnings concerning the fact that there will be a large number of our companies l…

There is, of course, no guarantee of future dealmaking, but this latest acquisition could foreshado…

According to research provider Dealogic, AbbVie's lead adviser Morgan Stanley, could stand to make …

Last week, the maker of Durex announced it was buying a baby-formula company for $17 billion and th…

AbbVie didn't want to take "a lot of binary risks" such as researching new, experimental drugs, "be…

Last week's rules are an addition to existing anti-inversion regulation, introduced in September 20…

In April, the drugmaker's $160 billion megamerger with Allergan was scrapped after the US Treasury …

Saunders: I understand why you would do it. To be fair, not all drugs are created equal. Some of th…

Simultaneously, a window for digital health and healthcare IT companies appears to be opening as we…

Guggenheim was founded in 1999 and has since grown to employ about 2,500 people throughout the US, …

Tax inversions were common in the 1990s but became a controversial topic in 2013 and 2014 when nume…

Actavis, which acquired Allergan in 2014 and kept the name, inverted to Ireland when it acquired Wa…

Allergan's tax domicile is in Ireland, which provides one of the most attractive havens for tax-inv…

Specialty pharma dealmaking fell off abruptly in 2017 with just $7 billion in deals, the lowest sin…

We have recently acquired a large position in Allergan and are very supportive of CEO Brent Saunder…

Argentina elected a conservative president that could turn the country on its head. "Conservative c…

On Wednesday, pharma giants Pfizer and Allergan announced they were scrapping their $160 billion me…

The minutes reiterated that the Fed is still concerned about negative spillover from the global eco…

Ray Dalio explains the biggest lessons he's learned since implementing his 10-year plan to turn ove…